Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity

• 收藏
• 分享

专利权人:

Novartis AG

发明人:

Szczudlo, Tomasz,Woodman, Richard,Yin, Ophelia

申请号：

AU2016216636

公开号：

AU2016216636B2

申请日:

2016.08.18

申请国别(地区):

AU

年份:

2018

代理人:

摘要：

#$%^&*AU2016216636B220180607.pdf#####H: rbr Intrwovn NRPortb DCC RBR I 0823705_l.DOC-17/08/2016 ABSTRACT The present invention relates to a regimen for the administration of a pyrimidylaminobenzamide of formula I as defined herein for the treatment of proliferative disorders, particularly solid and liquid tumors, and other pathological conditions mediated by the Bcr-Abl oncoprotein, the cell transmembrane tyrosine kinase receptor c-Kit, DDR1 (discoidin domain receptor 1), DDR2 (discoidin domain receptor 2) or PDGF-R (platelet derived growth factor receptor) kinase activity.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/